Blood-tumor barrier opening by MRI-guided transcranial focused ultrasound in a preclinical breast cancer brain metastasis model improves efficacy of combinatorial chemotherapy.

blood-brain barrer blood-tumor barrier (BTB) chemotherapeutic responses combinatorial therapeutic regime drug delivery efficacy focused ultrasound (MRgFUS)

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 21 11 2022
accepted: 02 02 2023
entrez: 27 2 2023
pubmed: 28 2 2023
medline: 28 2 2023
Statut: epublish

Résumé

Patients with metastatic breast cancer have high and continually increasing rates of brain metastases. During the course of the disease, brain metastases can occur in up to 30% of these patients. In most cases, brain metastases are diagnosed after significant disease progression. The blood-tumor barrier increases the difficulty of treating brain metastasis by preventing accumulation of chemotherapy within metastases at therapeutically effective concentrations. Traditional therapies, such as surgical resection, radiotherapy, and chemotherapy, have poor efficacy, as reflected by a low median survival rate of 5-8% after post-diagnosis. Low-intensity focused ultrasound (LiFUS) is a new treatment for enhancing drug accumulation within the brain and brain malignancies. In this study, we elucidate the effect of clinical LiFUS combined with chemotherapy on tumor survival and progression in a preclinical model of triple-negative breast cancer metastasis to the brain. LiFUS significantly increased the tumor accumulation of 14C-AIB and Texas Red compared to controls (p< 0.01). LiFUS-mediated opening of the BTB is size-dependent, which is consistent with our previous studies. Mice receiving LiFUS with combinatorial Doxil and paclitaxel showed a significant increase in median survival (60 days) compared to other groups. LiFUS plus combinatorial chemotherapy of paclitaxel and Doxil also showed the slowest progression of tumor burden compared to chemotherapy alone or individual chemotherapy and LiFUS combinations. This study shows that combining LiFUS with timed combinatorial chemotherapeutic treatment is a potential strategy for improving drug delivery to brain metastases.

Identifiants

pubmed: 36845739
doi: 10.3389/fonc.2023.1104594
pmc: PMC9950566
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1104594

Subventions

Organisme : NCI NIH HHS
ID : K00 CA253768
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121322
Pays : United States

Informations de copyright

Copyright © 2023 Arsiwala, Blethen, Wolford, Panchal, Sprowls, Fladeland, Kielkowski, Pritt, Wang, Wilson, Carpenter, Finomore, Rezai and Lockman.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Breast Cancer Res Treat. 2014 Aug;147(1):103-12
pubmed: 25106661
J Neurooncol. 2021 Apr;152(2):333-338
pubmed: 33512631
BMC Cancer. 2021 Sep 1;21(1):981
pubmed: 34470602
Fluids Barriers CNS. 2022 Sep 8;19(1):72
pubmed: 36076213
Radiat Oncol. 2021 Apr 15;16(1):73
pubmed: 33858474
Clin Cancer Res. 2010 Dec 1;16(23):5664-78
pubmed: 20829328
Sci Rep. 2020 Apr 14;10(1):6331
pubmed: 32286375
J Control Release. 2012 Nov 10;163(3):277-84
pubmed: 23000189
Ann Transl Med. 2018 May;6(9):163
pubmed: 29911111
Front Pharmacol. 2013 Nov 04;4:136
pubmed: 24312053
Theranostics. 2020 Jul 11;10(19):8821-8833
pubmed: 32754281
J Control Release. 2021 Sep 10;337:458-471
pubmed: 34324895
Nat Rev Clin Oncol. 2021 Nov;18(11):696-714
pubmed: 34253912
Sci Rep. 2016 Aug 11;6:31201
pubmed: 27510760
Pharmacol Res. 2018 Jun;132:47-68
pubmed: 29604436
Breast Cancer (Dove Med Press). 2022 Jan 10;14:1-13
pubmed: 35046721
BMC Cancer. 2018 Dec 7;18(1):1225
pubmed: 30526520
Front Oncol. 2022 May 19;12:903059
pubmed: 35677164
Neurooncol Adv. 2021 Nov 27;3(Suppl 5):v133-v143
pubmed: 34859240
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):140-154
pubmed: 30680954
Cancer Res. 2017 Jan 15;77(2):238-246
pubmed: 27815391
Trends Neurosci. 2022 Jun;45(6):459-470
pubmed: 35461727
Neoplasia. 2021 Jul;23(7):676-691
pubmed: 34139452
Curr Oncol. 2022 Nov 17;29(11):8846-8861
pubmed: 36421349
Clin Exp Metastasis. 2016 Apr;33(4):373-83
pubmed: 26944053
J Neurooncol. 2022 Jan;156(1):109-122
pubmed: 34734364
J Control Release. 2016 Sep 28;238:281-288
pubmed: 27496633
iScience. 2021 Dec 02;25(1):103558
pubmed: 34988401
Nat Cancer. 2022 Jan;3(1):3-5
pubmed: 35121997
Phys Med Biol. 2015 Mar 21;60(6):2511-27
pubmed: 25746014
Clin Cancer Res. 2021 Aug 1;27(15):4325-4337
pubmed: 34031054
Explor Target Antitumor Ther. 2022;3(2):240-251
pubmed: 35505937
BMC Cancer. 2019 Nov 12;19(1):1091
pubmed: 31718602
Br J Cancer. 2021 Jan;124(1):13-26
pubmed: 33239679

Auteurs

Tasneem A Arsiwala (TA)

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, United States.

Kathryn E Blethen (KE)

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, United States.

Cullen P Wolford (CP)

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, United States.

Dhruvi M Panchal (DM)

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, United States.

Samuel A Sprowls (SA)

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, United States.
Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.

Ross A Fladeland (RA)

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, United States.

Brooke N Kielkowski (BN)

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, United States.

Trenton A Pritt (TA)

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, United States.

Peng Wang (P)

Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States.

Olivia Wilson (O)

Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States.

Jeffrey S Carpenter (JS)

Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States.
Departments of Neuroscience, Neuroradiology, and Neurosurgery, West Virginia University, Morgantown, WV, United States.

Victor Finomore (V)

Departments of Neuroscience, Neuroradiology, and Neurosurgery, West Virginia University, Morgantown, WV, United States.

Ali Rezai (A)

Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States.
Departments of Neuroscience, Neuroradiology, and Neurosurgery, West Virginia University, Morgantown, WV, United States.

Paul R Lockman (PR)

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, United States.
Departments of Neuroscience, Neuroradiology, and Neurosurgery, West Virginia University, Morgantown, WV, United States.

Classifications MeSH